• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

二甲双胍与利拉鲁肽在人脐静脉内皮细胞（HUVECs）中发挥协同抗增殖作用。

Metformin exerts synergistic anti-proliferative effects with liraglutide in human umbilical vein endothelial cells (HUVECs).

作者信息

Shadboorestan Amir, Eftekhari Samane, Mottaghi-Dastjerdi Negar, Shahparvari Rezvan, Tarighi Parastoo, Jahandar Hoda, Faghihi Homa, Montazeri Hamed

机构信息

Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

These authors contributed equally to this work.

出版信息

Iran J Basic Med Sci. 2022 Apr;25(4):506-513. doi: 10.22038/IJBMS.2022.64117.14117.

DOI:10.22038/IJBMS.2022.64117.14117
PMID:35656067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9150808/
Abstract

OBJECTIVES

Metformin (Met) and liraglutide (Lira) have been approved to treat type 2 diabetes mellitus and have cardioprotective effects.

MATERIALS AND METHODS

Human umbilical vein endothelial cells (HUVECs) were incubated with Met, Lira, or their combination in this study.

RESULTS

Results showed that the synergistic inhibitory effect of the two drugs on HUVECs proliferation was significant (75%) after 48 hr drug exposure. In addition, either Lira or Met alone had a marked tendency to inhibit the migration of HUVECs (42% and 39%). Almost a complete inhibition (97%) was demonstrated in combinational use after 48 hr treatment. After combining these two drugs, the apoptosis rate raised to 68%, which was a significant approval of synergistic apoptosis induction of Met and Lira. The combinational group indicated a substantial increase in VEGF, PDGF, and MMP-9 at 24 hr compared with the control.

CONCLUSION

This study showed that combination therapy with Lira and Met could effectively reduce cell proliferation, induce apoptosis, and inhibit cell migration in the HUVECs. This study provides evidence to support using Met in combination with Lira as a treatment option for patients with type-2 diabetes and cancer.

摘要

目的

二甲双胍（Met）和利拉鲁肽（Lira）已被批准用于治疗2型糖尿病，且具有心脏保护作用。

材料与方法

在本研究中，将人脐静脉内皮细胞（HUVECs）与二甲双胍、利拉鲁肽或它们的组合一起孵育。

结果

结果显示，在药物暴露48小时后，两种药物对HUVECs增殖的协同抑制作用显著（75%）。此外，单独使用利拉鲁肽或二甲双胍均有明显的抑制HUVECs迁移的趋势（分别为42%和39%）。在48小时处理后，联合使用时几乎完全抑制（97%）。将这两种药物联合使用后，细胞凋亡率提高到68%，这显著证明了二甲双胍和利拉鲁肽协同诱导细胞凋亡。与对照组相比，联合用药组在24小时时VEGF、PDGF和MMP - 9显著增加。

结论

本研究表明，利拉鲁肽和二甲双胍联合治疗可有效降低HUVECs中的细胞增殖、诱导细胞凋亡并抑制细胞迁移。本研究为支持将二甲双胍与利拉鲁肽联合作为2型糖尿病和癌症患者的治疗选择提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/b910b4eef69f/IJBMS-25-506-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/bc3cdce89db9/IJBMS-25-506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/130299d030f4/IJBMS-25-506-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/56c4e0f47f40/IJBMS-25-506-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/51582e723039/IJBMS-25-506-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/f1d3ca7ee1e8/IJBMS-25-506-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/06b115a7566a/IJBMS-25-506-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/f583ede90489/IJBMS-25-506-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/b910b4eef69f/IJBMS-25-506-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/bc3cdce89db9/IJBMS-25-506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/130299d030f4/IJBMS-25-506-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/56c4e0f47f40/IJBMS-25-506-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/51582e723039/IJBMS-25-506-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/f1d3ca7ee1e8/IJBMS-25-506-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/06b115a7566a/IJBMS-25-506-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/f583ede90489/IJBMS-25-506-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/984d/9150808/b910b4eef69f/IJBMS-25-506-g008.jpg

相似文献

1
Metformin exerts synergistic anti-proliferative effects with liraglutide in human umbilical vein endothelial cells (HUVECs).二甲双胍与利拉鲁肽在人脐静脉内皮细胞（HUVECs）中发挥协同抗增殖作用。
Iran J Basic Med Sci. 2022 Apr;25(4):506-513. doi: 10.22038/IJBMS.2022.64117.14117.
2
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.利拉鲁肽联合二甲双胍与二甲双胍单药治疗对近期患有妊娠糖尿病的超重/肥胖妇女代谢状态和体重的影响：一项双盲、随机、安慰剂对照研究。
J Diabetes Complications. 2020 Apr;34(4):107548. doi: 10.1016/j.jdiacomp.2020.107548. Epub 2020 Feb 1.
3
Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.比较二甲双胍和利拉鲁肽对糖耐量受损大鼠心脏保护作用的评价。
Sci Rep. 2021 Mar 23;11(1):6700. doi: 10.1038/s41598-021-86132-2.
4
Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway.利拉鲁肽通过 TRIB3/NF-κB 信号通路改善高糖诱导的血管内皮损伤。
In Vitro Cell Dev Biol Anim. 2024 Oct;60(9):1046-1057. doi: 10.1007/s11626-024-00947-7. Epub 2024 Jul 22.
5
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.二甲双胍与二甲双胍联合利拉鲁肽对超重多囊卵巢综合征患者性腺和代谢特征的影响。
Front Endocrinol (Lausanne). 2022 Aug 17;13:945609. doi: 10.3389/fendo.2022.945609. eCollection 2022.
6
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.短期联合利拉鲁肽和二甲双胍治疗可显著减轻多囊卵巢综合征肥胖妇女的体重，这些患者既往对二甲双胍反应不佳。
Eur J Endocrinol. 2014 Feb 7;170(3):451-9. doi: 10.1530/EJE-13-0797. Print 2014 Mar.
7
Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.二甲双胍与利拉鲁肽通过 GLP-1 受体和 PKA 信号通路协同作用对抗血管内皮功能障碍。
Sci Rep. 2017 Feb 1;7:41085. doi: 10.1038/srep41085.
8
Liraglutide Activation of AMP-Activated Protein Kinase-Hypoxia Inducible Factor-1α-Heme Oxygenase-1 Signaling Promotes Wound Healing by Preventing Endothelial Dysfunction in Diabetic Mice.利拉鲁肽激活AMP活化蛋白激酶-缺氧诱导因子-1α-血红素加氧酶-1信号通路，通过预防糖尿病小鼠内皮功能障碍促进伤口愈合。
Front Physiol. 2021 Aug 16;12:660263. doi: 10.3389/fphys.2021.660263. eCollection 2021.
9
[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].利拉鲁肽联合人脐带间充质干细胞治疗对2型糖尿病患者糖代谢及β细胞功能的影响
Zhonghua Nei Ke Za Zhi. 2016 May 1;55(5):349-54. doi: 10.3760/cma.j.issn.0578-1426.2016.05.004.
10
Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states.重组人血管内皮抑制素与多西他赛对不同生长状态人脐静脉内皮细胞作用的比较。
Chin Med J (Engl). 2011 Sep;124(18):2883-9.

引用本文的文献

1
The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.胰高血糖素样肽-1受体激动剂利拉鲁肽对高糖诱导的炎症、细胞凋亡、氧化应激和NLRP3信号传导的影响
Cell Biochem Biophys. 2025 Apr 11. doi: 10.1007/s12013-025-01742-1.

本文引用的文献

1
Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.利拉鲁肽（一种胰高血糖素样肽-1 受体激动剂）与多西他赛联合应用对 LNCaP 前列腺癌细胞系的协同抗肿瘤作用。
Eur J Pharmacol. 2020 Jul 5;878:173102. doi: 10.1016/j.ejphar.2020.173102. Epub 2020 Apr 10.
2
Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway.利拉鲁肽通过 JAK2/STAT3 信号通路促进人脐静脉内皮细胞的血管生成能力。
Biochem Biophys Res Commun. 2020 Mar 12;523(3):666-671. doi: 10.1016/j.bbrc.2020.01.004. Epub 2020 Jan 14.
3
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.
肿瘤血管生成与癌症治疗的抗血管生成策略
J Clin Med. 2019 Dec 29;9(1):84. doi: 10.3390/jcm9010084.
4
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.二甲双胍在结直肠癌中的作用：分子机制、临床前和临床方面。
J Exp Clin Cancer Res. 2019 Dec 12;38(1):491. doi: 10.1186/s13046-019-1495-2.
5
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.内皮素 GLP-1（胰高血糖素样肽-1）受体通过利拉鲁肽介导实验性高血压小鼠的心血管保护作用。
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):145-158. doi: 10.1161/atv.0000615456.97862.30. Epub 2019 Nov 21.
6
Liraglutide Increases VEGF Expression CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury.利拉鲁肽增加缺氧/复氧损伤诱导的VEGF表达及CNPY2-PERK通路。
Front Pharmacol. 2019 Jul 24;10:789. doi: 10.3389/fphar.2019.00789. eCollection 2019.
7
GDF15 induced apoptosis and cytotoxicity in A549 cells depends on TGFBR2 expression.GDF15 通过激活 TGFBR2 诱导 A549 细胞凋亡和细胞毒性。
Cell Biochem Funct. 2019 Jul;37(5):320-330. doi: 10.1002/cbf.3391. Epub 2019 Jun 7.
8
Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling.AhR 和 NFAT 阻断抑制 MDA-MB-231 细胞的侵袭和迁移：AhR/NFAT1/β4 整合素信号的作用。
J Appl Toxicol. 2019 Feb;39(2):375-384. doi: 10.1002/jat.3728. Epub 2018 Oct 7.
9
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.二甲双胍抑制胰腺癌基因工程小鼠模型中的肿瘤血管生成，并增强吉西他滨的化疗敏感性。
Life Sci. 2018 Sep 1;208:253-261. doi: 10.1016/j.lfs.2018.07.046. Epub 2018 Jul 25.
10
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.利拉鲁肽与二甲双胍协同抑制胰腺癌细胞。
PLoS One. 2018 Jun 13;13(6):e0198938. doi: 10.1371/journal.pone.0198938. eCollection 2018.